PMID- 21386703
OWN - NLM
STAT- MEDLINE
DCOM- 20120124
LR  - 20161020
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 19
IP  - 5
DP  - 2011 Oct
TI  - HER2 testing: how to reach a high concordance rate between immunohistochemistry 
      and fluorescence in situ hybridization.
PG  - 424-30
LID - 10.1097/PAI.0b013e31820b62be [doi]
AB  - BACKGROUND: The concordance rate between immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH) for human epidermal growth factor 
      receptor-2 (HER2) is still a major clinical concern. We describe a new criteria 
      evaluating HER2 IHC. MATERIALS AND METHODS: We expanded the equivocal category to 
      include the American Society of Clinical Oncology and College of American 
      Pathologists equivocal category and cases with 3+ between 30% to 90% of tumor 
      cells and 2+ in >/=1% of tumor cells. Then, we prospectively evaluated 106 cases 
      with FISH. RESULTS: There were 2 categories that were not required to be tested 
      by FISH based on American Society of Clinical Oncology and College of American 
      Pathologists criteria. The first category, cases with 2+staining between >/=1% and 
      <10%. In this category, there were 15 cases, 2 (13.3%) had HER2 amplification by 
      FISH. The second category, cases with 3+ staining between 30% and 90%. In this 
      category, there were 16 cases, 5 (31.3%) were not amplified and 1 (6.3%) was 
      borderline. CONCLUSIONS: Expanding the equivocal category could increase the 
      concordance rate between IHC and FISH with minimal additional cost.
FAU - Khoury, Thaer
AU  - Khoury T
AD  - Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. 
      thaer.khoury@roswellpark.org
FAU - Kulkarni, Swati
AU  - Kulkarni S
FAU - Morrison, Carl
AU  - Morrison C
FAU - Bshara, Wiam
AU  - Bshara W
FAU - Zakharia, Yousef
AU  - Zakharia Y
FAU - Edge, Stephen
AU  - Edge S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Diagnostic Techniques and Procedures/standards
MH  - False Negative Reactions
MH  - False Positive Reactions
MH  - Female
MH  - Humans
MH  - *Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - *Receptor, ErbB-2/analysis
MH  - Research Design
MH  - United States
MH  - United States Food and Drug Administration
EDAT- 2011/03/10 06:00
MHDA- 2012/01/25 06:00
CRDT- 2011/03/10 06:00
PHST- 2011/03/10 06:00 [entrez]
PHST- 2011/03/10 06:00 [pubmed]
PHST- 2012/01/25 06:00 [medline]
AID - 10.1097/PAI.0b013e31820b62be [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2011 Oct;19(5):424-30. doi: 
      10.1097/PAI.0b013e31820b62be.